Last quarter (Q4 2023), Amylyx Pharmaceuticals Inc's total revenue was $108.45M, an increase of 395.54% from the same quarter last year. In Q4, Amylyx Pharmaceuticals Inc's net income was $4.73M. See Amylyx Pharmaceuticals Inc’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	$ 380.79M	$ 380.79M	$ 22.23M	$ 0.00	$ 0.00
Cost of Revenue	$ 25.44M	$ 25.44M	$ -2.99M	-	-
Gross Profit	$ 355.35M	$ 355.35M	$ 19.24M	-	-
Operating Expense	$ 316.54M	$ 316.54M	$ 220.58M	$ 82.69M	$ 39.01M
Operating Income	$ 38.80M	$ 38.80M	$ -201.34M	$ -82.69M	$ -39.01M
Net Non Operating Interest Income Expense	$ 16.16M	$ 16.16M	$ 4.29M	$ 36.00K	$ -2.27M
Other Income Expense	$ 660.00K	$ 660.00K	$ 551.00K	$ -5.28M	$ -1.00M
Pretax Income	$ 54.30M	$ 54.30M	$ -197.60M	$ -87.93M	$ -42.28M
Tax Provision	$ 5.03M	$ 5.03M	$ 774.00K	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ 49.32M	$ 49.27M	$ -198.38M	$ -87.93M	$ -42.28M
Basic EPS	$ 0.73	$ 0.73	$ -3.39	$ -1.59	$ -0.93
Diluted EPS	$ 0.70	$ 0.70	$ -3.39	$ -1.59	$ -0.93
Basic Average Shares	$ 268.94M	$ 67.23M	$ 58.50M	$ 55.22M	$ 45.55M
Diluted Average Shares	$ 279.97M	$ 69.99M	$ 58.50M	$ 55.22M	$ 45.55M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 128.95M	$ 341.98M	$ 217.59M	$ 82.69M	$ 39.01M
Net Income From Continuing And Discontinued Operation	$ 49.27M	$ 49.27M	$ -198.38M	$ -87.93M	$ -42.28M
Normalized Income	$ 36.67M	-	-	$ -87.93M	$ -41.01M
Interest Expense	-	-	-	$ 0.00	$ 2.29M
EBIT	$ 47.82M	$ 54.30M	$ -197.60M	$ -87.93M	$ -39.99M
EBITDA	$ 21.01M	$ 45.45M	$ -199.17M	$ -87.88M	$ -39.99M

Currency in USD

Amylyx Pharmaceuticals Inc Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing